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Introduction: Desmopressin is used for nocturnal enuresis treatment in children. In this study, 
we investigated the pharmacokinetics of two formulations: a tablet and a lyophilisate, in both fasted 
and fed children. 
Methods: Previously published data from two studies (22 children aged 6 to 16 yr and 25 
children aged 6 to 13 yr) were analyzed using population pharmacokinetic modeling. A 1-
compartment model with first order absorption was fitted to the data. Covariates were selected 
using a forward selection procedure. The final model was evaluated, and sensitivity analysis was 
performed to improve future sampling designs. Simulations were subsequently performed to 
further explore the relative bioavailability of both formulations and the food effect.  
Results:  The final model described the desmopressin plasma concentrations adequately.  
Formulation and fed state were included as covariates on the relative bioavailability. The 
lyophilisate was on average 32.1 % more available than the tablet, and fasted children exhibited an 
average increase in relative bioavailability of 101%, compared to fed children. Body weight was 
included as a covariate on distribution volume, using a power function with exponent 0.402. 
Simulations suggest both the formulation and the food effect are clinically relevant.  
Conclusions: Bioequivalence data of two formulations of the same drug in adults, cannot be 
readily extrapolated to children. This is the first study in children suggesting that the two 
desmopressin formulations in children are not bioequivalent at the currently approved dose levels. 
Furthermore, the effect of food intake was found to be clinically relevant. Sampling times for a 
future study were suggested. This sampling design should result in more informative data and 
consequently generate a more robust model. 
Key points 
 Population pharmacokinetic modeling was applied to pediatric desmopressin PK data and used to 
extract more information out of existing pediatric drug data, generate new information and 
improve the collection of future information. 
 In this study it was found that the established bioequivalence of desmopressin in adults might be 
different in the pediatric population. A profound food effect was also quantified. 
 In order to make solid conclusions regarding desmopressin efficacy in children, PK and PD data 
should be gathered simultaneously in a well-designed study, for which some design suggestions 
are presented in this paper. 
 
Abbreviations 
AIC Akaike’s Information Criterion 
AUC area under the plasma concentration-time 
curve 
BCa bias-corrected bootstrap with acceleration 
constant 
CI confidence interval 
Cmax maximum drug concentration 
CN condition number 
CTS Clinical Trial Simulation 
DDAVP Desmopressin 
EI Elasticity Index 
FIM Fisher Information Matrix  
IIV interindividual variability 
LSA Local Sensitivity Analysis 
MNE monosymptomatic nocturnal enuresis  
NPDE normalized prediction distribution error 
NPC numerical predictive check  
OED Optimal Experimental Design 
OFV Objective Function Value 
PD pharmacodynamics 
PK pharmacokinetics 
PopPK population pharmacokinetics 
PSN Perl-Speaks-Nonmem 
RSE relative standard error 
VPC Visual Predictive Check 
 
I. Introduction 
Off-label use of drugs in the pediatric population is widespread: 50-90% of prescriptions in 
pediatrics are off-label and/or unlicensed [1]. The project SAFE-PEDRUG (http://safepedrug.eu) 
aims to reinvent the strategy for pediatric drug research using a rational combination of bottom-
up and top-down approaches, starting from pediatric specificities and opportunities. 
Desmopressin (1-deamino-8-D-arginine vasopressin, DDAVP), one of the drugs under study, is a 
synthetic vasopressin analogue acting on the V2 -receptors located in the collecting ducts of the 
kidney. It has been applied clinically for more than 30 years, using a range of different 
formulations: intranasal solution (since 1972), injectable solution (since 1981), tablets (since 
1987), and most recently, an oral lyophilisate (since 2005) [2]. 
Initially, DDAVP was developed to treat adult patients with central diabetes insipidus. 
Following the observation by Rittig et al., that children with enuresis showed a significantly 
lower nocturnal increase in arginine-vasopressine (AVP) [3], it was subsequently used for an 
indication primarily seen in children; enuresis nocturna. Until now, DDAVP is the only drug 
therapy with evidence level 1, grade A recommendation, for the indication of monosymptomatic 
nocturnal enuresis (MNE) [4]. Reported adverse events are generally described as mild, and 
include headache, abdominal pain, nausea, and - typically for the nasal spray [5] - nasal 
epistaxis, and congestion/rhinitis. Hyponatremia remains an infrequent but very serious adverse 
event associated with the antidiuretic effect of DDAVP treatment [6]. It has been reported after 
intake of DDAVP with simultaneous excess intake of fluids [7, 8]. In 2007, the US Food and Drug 
Administration requested an update of the summary of product characteristics for DDAVP nasal 
spray following increasing reports on hyponatremia [7], [9]. Since then, the DDAVP spray is no 
longer indicated for the treatment of MNE, or in patients at risk for hyponatremia in the USA 
and most European countries [9]. 
Currently, two oral formulations of DDAVP are labeled for the indication of MNE: a tablet 
(TAB) and a lyophilisate (MELT). Their bioequivalence at dose strengths of 200 µg and 120 µg, 
respectively, has been established in adults [10, 11] but not in children. In a previous study, the 
lyophilisate has been shown to have a superior effect on diuresis in children, which was 
hypothesized to arise from a less pronounced food interaction [12]. DDAVP is to be taken in a 
fasted state before bedtime, which is challenging in young children, due to the short time 
between the last meal in the evening and bedtime. This suggests that the food effect on DDAVP 
PK/PD should be investigated more thoroughly, as this effect has been established before in 
adults [13] but not in children. A published pilot study from our group investigated the PK of 
both the tablet and lyophilisate formulation in children whom were fed a standard meal [14]. 
However, only an influence of the formulation on the variability in PK was detected and no 
fasted control group was included in the analysis. Additionally, suggestions of a body-size effect 
were found. Given these results, it was decided to set up a new study using a more elaborate 
sampling scheme to investigate these effects more thoroughly. This paper describes a model-
based analysis we set up to increase the efficiency of this future trial. 
The purpose of this analysis was two-fold: 
1. By pooling previously published pediatric data on DDAVP PK and using a population 
pharmacokinetics (PopPK) approach, a more in-depth understanding of the effect of 
formulation, concomitant food intake and patient size on DDAVP PK could be obtained. 
2. The developed model was subsequently used to formulate experimental design strategies 
for the follow-up clinical trial, so that the analysis objectives could be reached as 
efficiently as possible. 
 
II. Materials and Methods 
I.  Study data 
Only two studies on orally formulated DDAVP PK in children have been published [14], 
[15], both of which are included in the current analysis. Østerberg et al. compared the 
PK of an oral lyophilisate in 72 children with MNE to the PK in 28 healthy, adult 
volunteers using a double-blind, randomized, parallel group, multi-center study [15]. Data 
from 25 of these children were available for the current analysis. In a second study, De 
Bruyne et al. used a two-period crossover design to compare the oral lyophilisate to a 
tablet formulation in children with MNE. Of the 23 children that were included, 22 
successfully completed the study, of which the data were available for the current 
analysis [14]. The 2 datasets are compared in Table 1. 
 
Table 1: Characteristics of the Østerberg and the De Bruyne datasets [14-15]. 
 Østerberg et al. De Bruyne et al. 
n patients 25 22 
Age (years) (median [min-max]) 9.7 [6.7 - 13] 12.5 [7 - 16] 
Weight (kg) (median [min-max])  32 [25 - 63] 51  [24 - 82] 
Sex 5F and 20M 4F and 18M 
Height (cm) (median [min-max]) 138 [121 - 165] 162 [115 - 186] 
Formulation Lyophilisate Lyophilisate and tablet 
(2 weeks between treatments) Dose (µg) 0 - 480 200 (tablet) 
120 (lyophilisate) 
Fed state Fasted Fed (standardized 510 kcal meal) 
Average n samples per patient 1.9 3 per formulation 
Sampling times 0 - 24 h 1, 2 and 6 h 
Analytical method Radioimmunoassay LC-MS/MS 
Linear range 0.8 - 100 pg mL-1 2.00 - 100 pg mL-1 
 
II. Model development 
A 1-compartment model with first-order absorption was chosen as a starting point. 
The log-transform-both-sides (LTBS) approach was used, meaning that the logarithm of 
the plasma concentrations was modelled. The development of the population 
model proceeded iteratively, and the inter-individual variability (IIV) was assumed to follow a 
log-normal distribution. A proportional residual error model (= additive error model in the log 
domain) was used throughout the entire process. Once an appropriate mixed effects model 
was obtained, covariate relationships were investigated using a forward selection, 
adding them to the model one at a time and selecting the models with the best 
performance metrics to proceed with. The covariates that were tested, were: 
formulation (MELT), fed state (FED), age (AGE), body weight (WT), sex (SEX), and Tanner 
Index (TAN). 
The decision to include or exclude certain model components was guided by several 
performance metrics: the Objective Function Value (OFV), Akaike’s Information Criterion (AIC), 
the condition number (CN), and the relative standard error (RSE) of the parameter estimates, 
obtained through the covariance step in NONMEM. A drop in OFV of 3.84 was assumed to 
indicate a significantly better fit. Both the OFV and the AIC are based on likelihood ratio tests, 
that cannot be reliably used to guide in-/exclusion of IIV parameters, especially for sparse data 
[16]. Thus, for those parameters, decisions were made based on RSE and CN (both should be as 
low as possible), and standard goodness of fit plots (plots of the observed concentrations versus 
population- and individual-predicted   concentrations, and plots of the residuals). 
 
III. Model evaluation 
In order to establish confidence in the final model, different evaluation techniques were 
applied. A visual and numerical predictive check (VPC and NPC) were performed, without 
binning or calculating confidence intervals (CIs) on the (sparse) data. Individual and population 
predictions versus observations plots were also used, and bootstrap analysis was performed. For 
the latter analysis, 1000 datasets of 47 subjects were resampled with replacement from the 
original dataset. The bias-corrected bootstrap with acceleration constant (BCa ) method was 
used in order to obtain second-order correct 90% CIs around the parameter estimates [17]. This 
method corrects for bias and skewness in the standard bootstrap CIs and thus provides a more 
reliable estimate of the parameter CIs. 
The last evaluation technique consisted of normalized prediction distribution error (NPDE) 
analysis. For this method, the final model was simulated 1000 times using the same design as the 
original dataset, after which the NPDEs were obtained using the table step in NONMEM [18,19]. 
Under the null hypothesis that the model describes the data, the distribution of NPDEs should be 
equal to the standard normal distribution N(0,1). 
This hypothesis was formally tested using the Wilcoxon signed-rank test (H0 : µ = 0), the Fisher 
variance ratio test (H0 : σ
2 = 1), and the Shapiro-Wilks normality test (H0 : Z ∼ N (µ, σ
2 )). 
 
IV. Sensitivity analysis and sampling design 
Sensitivity analysis was performed on the final model. This means, in the broadest sense, 
that the influence of the different model inputs on the output was studied in a quantitative way. 
The results can point to parameters that can be excluded (model reduction) or errors in model 
structure. Furthermore, these results show at which point in time the model output is the most 
sensitive to an input, and thus when the most information can be gained from an experiment. 
Therefore, this technique can be used to perform Optimal Experimental Design (OED). In 
general, two kinds of sensitivity analysis exist: local and global sensitivity analysis [24–26], of 
which the former was performed in this study.  
In this Local Sensitivity Analysis (LSA), the influence of the model parameters was examined 
in a small window around the nominal (estimated) value. Because of this small perturbation, the 
change in response can be described by a first order approximation, and the sensitivity of the 
output to each input can be calculated using the partial derivative of that output to each 
specific parameter. 
In order to be able to compare these sensitivities, they were normalized to Elasticity Indices 
(EIs), which have the same units (pg ml−1) as the output (see equation 1). These EIs can be 
compared between different parameters, independent of the parameter values. 
 
Equation 1: Elasticity Indices 
The results of the LSA were compared to an OED performed using PopED for R [18]. In this 
design, optimal sampling times were calculated based on optimization of the population Fisher 
Information Matrix (FIM) [25], which should result in more efficient designs than the use of a 
LSA on its own. Five iterations of a sequence of random search (300 iterations), stochastic 
gradient (150 iterations) and linear search (step size = 40) algorithms were used to identify the 
optimal design. 
 
V. Simulation-based analysis 
Once confidence in the model had been achieved during the evaluation step, it was used for 
simulation. On the one hand, the established average bioequivalence of 120 µg lyophilisate and 
200 µg tablet [10], [11], and the food effect [13] previously reported in adults were further 
analyzed for their clinical relevance in this pediatric dataset. On the other hand, the optimal 
sampling times found before were applied in a sample size calculation for a bioequivalence trial. 
To investigate the effect of the 2 DDAVP formulations and of the food intake, clinical trial 
simulations (CTSs) were performed. For this, 20 patients were sampled randomly (by body 
weight, as no other covariates were present in the final model) from a lognormal body weight 
distribution for children aged 7 to 16 year [23]. These 20 patients then were simulated to 
undergo 4 scenarios:  administration of 120 µg lyophilisate while fed (MELT + FED), 200 µg 
tablet while fed (TAB + FED), 120 µg lyophilisate while fasted (MELT + FAST) and 200 µg tablet 
while fasted patients (TAB + FAST). For each scenario and patient, the area under the plasma 
concentration-time curve (AUC0-∞) and maximum drug concentration (Cmax), and their 
logarithms were calculated from 8 simulated samples, taken at the optimal times determined 
by the LSA. As is recommended by the FDA [24], an additional sample at 24h was included in 
this design, to minimize extrapolation in the AUC calculation. 
For each trial of each individual, the following ratios were calculated to separate the 







Where A = FED or FAST and B = TAB or MELT. Two formulations are considered bioequivalent 
when the 90% CIs of the geometric mean of their AUC- and Cmax -ratios fall between 80% and 
125% [20, 21].  As these means are equal to the log-average, the CIs on the log-ratios were 
calculated using the modified Cox method (equation 2, [27]) which were subsequently 
exponentiated to obta i n  the normal CI. 
 
) 
Equation 2: Modified Cox method 
Where Ŷ is the mean of the log-ratios, σ is the standard deviation, n is the sample size (20), and t is 
the 90% value of the two-sided t-distribution with n − 1 degrees of freedom (≈ 1.33 for n = 20). 
The CIs for the food effect were calculated and interpreted in the same way, as is recommended 
by the FDA [28], resulting in the acceptance or rejection of bioequivalence and food effect for that 
particular trial. These trials were repeated 1000 times and the resulting CIs were then summarized 
by taking the median of the lower, upper and mean values. Furthermore, the percentage trials 
which resulted in acceptance of bioequivalence were calculated. Eventually, a sample size 
calculation for a crossover two-period bioequivalence study with doses suggested by the 
estimated model parameters was performed, both in fed and fasted patients. This sample size 
calculation took parameter uncertainty into account by sampling each parameter from a 
multivariate normal distribution based on the variance-covariance matrix, resulting in 1000 
parameter sets for each number of individuals. 
 
VI.. Software 
Model development and parameter estimation were performed using NONMEM v. 7.3 [29], with 
FOCE as estimation algorithm, accessed with the software Perl-Speaks-Nonmem (PSN) [30], 
embedded in the workbench Piraña [31]. RStudio (v. 0.98, http://www.rstudio.com/) was used to 
prepare the datasets, perform the simulations, and post-process all results, which included the 
statistical calculations and plot generation. The LSA was performed using the biointense model 
environment in Python. This package is “an object oriented python implementation for model 
building and analysis, focusing on sensitivity and identifiability analysis” [32]. It was accessed using 
Spyder v. 2.3.3 [33]. 
 
III. Results 
I.  Model development 
The model development path is depicted in Table 2. The available data was used to its limits, 
as not all random effects could be estimated without inflating the condition number. This is 
caused by the sparseness of the data. After model 29 was run (the final model), other covariates 
(age, tanner index, BMI and sex) were tested on all the fixed effects. Different relations (Emax, 
sigmoidal, exponential and allometric scaling) were also tested for these covariates. None of 
them improved the model significantly and often a significant increase in OFV was found 
instead (data not shown). Therefore, model 29 was chosen as the final model. The final model 
structure and parameters are found in Table 3.  
Table 2: Model development path to the final model 
Run # Ref # OFV ΔOFV AIC CN Max(RSE) Description 
1  -4.482  5.518   
One compartmental model with first 
order   absorption. Estimation of fixed 
effects. 
7 1 -32.237 -27.755 -20.237 34 35% Estimation of IIV on F1 + fixed effects. 
11 1 -4.482 0 3.518   Fix F1 (no IV data) to 1. 
15 11 -32.237 -27.755 -22.237 17 35% Estimation of IIV on F1 + fixed effects. 
17 15 -35.976 -3.739 -23.976 34 77% 
Estimation of IIV on F1 and Vd + fixed 
effects. 
21 11 -49.413 -44.931 -37.413   
Addition of formulation effect covariate 
to model before estimating IIVs, 
estimate fixed effects and IIV on 
formulation effect. 
23 21 -70.275 -20.862 -56.275 32 36% 
Estimation of IIV on formulation effect 
and Vd + fixed effects. 
27 23 -85.594 -15.319 -69.594 84 56% 
Addition of food effect covariate to 
model before estimating IIV on 
formulation effect and Vd + fixed effects. 
28 27 -83.954 1.64 -67.954 84 47% 
Put IIV on F1 (lumped) instead of on 
formulation effect. 
29 28 -87.758 -3.804 -69.758 40 46% 
Addition of body weight as a covariate 
to 
Vd using a power function (Final Model). 
 
Fig. 1: VPC for the different scenarios present in the data. The line represents the median model prediction for each 
scenario, the grey area represents the 90% prediction interval.  
 
Fig. 2: VPC for all data pooled together. The line represents the total median model prediction, the grey area represents 






Fig. 3: Population and individual predictions versus observed concentrations. The dotted line represents the unity line 
and the full line represents a Loess smoother through the data points. 
 
Fig. 4: NPDE distribution (left) and QQ-plot (right). µ = 0.00569, σ = 1.01. 
 
II. Model evaluation 
In Figure 1, VPCs for the three different scenarios present in the data (MELT + FAST, MELT + 
FED, and TAB + FED) are shown. The model seems to perform best for patients who receive the 
lyophilisate formulation. The numerical predictive check was performed on the full VPC (Figure 
2). 2.80% of the observations lay above the 90% PI and 3.50% of the observations lay below the 
90% PI, indicating good model performance. Figure 3 shows the population and individual 
predictions plotted against the observations: no significant deviations from the line of unity are 
seen. 
The 90% CIs of the BCa bootstrap analysis (818/1000 runs completed minimization) are 
included in Table 3. The bootstrap estimates deviated between −7.53% and +4.50% from the 
model estimates, with an average deviation of 0.21%. Bootstrap-estimated relative standard 
errors (between 18.2% and 84.9%) were consistently higher than the standard errors estimated 
in NONMEM (between 10% and 46%). 
The NPDE results are shown in Figure 4. No significant deviations from the standard normal 
distribution could be detected, as is shown in Table 4. 
 
Table 3: Population pharmacokinetic model parameter estimates and bootstrap values. 
Parameter Estimate [%RSE] Bootstrap [90%CI] 
        CL/F = θ1 ∗ eη1 4982 L/h [12%] 4964 [4002 – 5820] 




23346 L [13%] 23345 [17817 – 28366] 
ka = θ3 ∗ eη3 1.65 h-1 [25%] 1.72 [1.01 − 2.58] 
F = (θ4 + θ5 ∗ MELT 
+θ6 ∗ FAST ED) ∗ eη4 ) 
1 FIX 1 FIX 
Influence of MELT (θ5) 0.321 [46%] 0.333 [0.0486 − 0.548] 
Influence of fasted state  
(θ6) 
1.01 [25%] 1.05 [0.579 − 1.45] 
Influence of weight (θ7) 0.402 [44%] 0.397 [0.118 − 0.731] 
IIV on C L 0 FIX 0 FIX 




25.2% [16.5% − 46.0%] 
IIV on ka 0 FIX 0 FIX 




21.1% [11.6% − 31.2%] 
Proportional residual error 38.5 CV% [14%] 37.8 CV% [34.4% – 44.1%] 
 
 
Table 4: Formal tests for H0 : NPDE-distribution = N(0, 1) 
Test H0 Value p-value Conclusion 
Wilcoxon signed-rank µ = 0 V = 5153 0.994 H0 cannot be rejected 
Fisher variance ratio σ2 = 0 F = 1.03 0.770 H0 cannot be rejected 
Shapiro-Wilks Z ~N(μ, σ2) W = 0.989 0.315 H0 cannot be rejected 
 
 
                                                          
2
 Coefficient of variation, calculated as  
III. Sensitivity analysis and sampling design 
The calculated EIs versus time are presented in Figure 5. Sensitivity function optima are 
marked with green stars. These optima are considered good sampling time points, as the 
output is the most sensitive to a certain parameter at those points, enabling optimal estimation 
of this parameter [22], [34]. The most important parameters (i.e. the one with the largest area 
under the sensitivity function) are the relative bioavailability and dose, the effect of food intake, 
Vd, and CL.  
Based on this analysis, sample times for a subsequent clinical study with rich sampling were 
suggested. Intensive sampling of the absorption part (< 3 h) is needed to capture all information 
present during this part of the PK profile. The elimination phase is much less informative and 
should not be sampled equally intensive. The proposed sampling scheme for a study with 8 
time points was 0.25 h, 0.5 h, 1 h, 1.5 h, 2 h, 3 h, 5 h and 6 h. 
The results of the FIM-based OED are shown in Figure 6. The resulting sampling scheme for 
8 time points is presented in Table 5. The optimal design was 1.34 times more efficient than the 
initial (LSA-derived) design. Merging of optimal times close to each other resulted in minimal 
loss of efficiency. This reduced design was 1.22 times more efficient than the initial LSA-derived 
design. 
 
Table 5: Optimal experimental design 
Scenario Sample times (h) 
MELT + FED 0.475 0.8 0.8 2.15 2.375 4.4 5.5 5.8 
MELT + FASTED 0.3259 0.475 0.8 1.85 2.075 5.8 5.8 5.8 
TAB + FED 0.4 0.65 0.8 2.025 2.15 6.1 7.2 7.2 
TAB + FASTED 0.525 0.525 0.8 1.735 2.053 4 6.85 7.8 
 
Fig. 5:  Relative sensitivity of the predicted DDAVP plasma concentrations to the model parameters. The blue pentagons 
refer to original sample times [8], whereas the green stars represent proposed optimal sampling times. 
 
 
Fig. 6: FIM-based optimal sampling design. The profiles are expected population averages for the different scenarios and 
the circles are suggested sampling times. 
 
IV. Simulation-based exploration 
Bioequivalence and food effect 
The CTSs are summarized in Figure 7. In none of the simulated trials, the different formulations/ 
fed states were found to be bioequivalent. The simulations, in Figure 7, show how the food effect 
is more apparent than the formulation effect. Simulated subjects experience a higher exposure to 
DDAVP when they are fasted than when they have received a standard meal.  In addition, a 200 µg 
tablet results in a higher exposure compared to a 120 µg lyophilisate while in adults, these dose 
levels resulted in equivalent exposure. In order to quantify the relevance of these effects, the 




AUC − ratio = 138% [133% − 144%] 
Cmax − ratio = 144% [135% − 153%] 
Food effect: 
AUC − ratio = 194% [187% − 201%] 
Cmax − ratio = 202% [190% − 215%] 
When applying EMA and FDA guidelines to the results of this simulation study, a significant food 
effect is concluded to be present for DDAVP in children [20, 21]. The established bioequivalence of 
200 µg tablet and 120 µg lyophilisate is also rejected, based on these simulations. It can thus be 
expected that in a real trial, bioequivalence between the 200 µg tablet and 120 µg lyophilisate 
cannot be claimed. Indeed, a point estimate of 138% suggests that the ratio of dose strengths (120 
µg lyophilisate versus 200 µg tablet) is suboptimal and a higher lyophilisate dose is needed to 
reach similar exposure as compared to the 200 µg tablet. Using the parameter estimate of the 
formulation effect (0.3208), we calculated that the equivalent dose of lyophilisate to 200 µg tablet 
is 151.4 µg. At this point, a new CTS was performed using these newly suggested dose strengths. 
The results are shown in Figure 8 and show an almost complete overlap of the concentration-time 




Fig. 7: Simulated DDAVP plasma concentrations for the four different scenarios (120 µg lyophilisate, 200 µg tablet). The 
lines represent the average response and the colored areas represent the 95% prediction intervals. On the left, the effect of 
the different formulations is depicted; on the right, the food effect is shown. 
 
Fig. 8: Simulated DDAVP plasma concentrations for the four different scenarios (150 µg lyophilisate, 200 µg tablet).  
In order to further support this new dose, a proper two-period cross-over bioequivalence trial should 
be performed with 150 µg lyophilisate and 200 µg tablet. A power curve was approximated for this 
design, by simulating this trial 1000 (parameter uncertainty) * 1000 (IIV) times for 1 up to 50 patients 
and calculating the power as the number of times bioequivalence was proven divided by the total 
amount of trials (1000). The results for fed patients are shown in Figure 9: approximately 20 patients 
would be needed for a median power of 80%. Using fasted patients, approximately 250 patients 
would be needed (results not shown). 
  
Fig. 9: Approximated power curve for a two-period cross-over bioequivalence trial with fed patients. The colored areas 
represent the 90% prediction interval. 
 
IV. Discussion 
In this study, we investigated the pharmacokinetics of desmopressin in a pediatric population. In 
order to do this, two data sets of previously published clinical trials were combined, enabling the 
use of the specifics (e.g. food intake or not, sampling schemes,...) of both data sets and thus the 
extraction of more information from the data. Nonlinear mixed effects modeling was used and a 1-
compartmental model with first order absorption was able to describe the data well. In previous 
studies, more complex models such as a 2-compartmental model [35], a 3-compartmental model 
[36] and a 1-compartmental model with transit compartments [15] have been used to describe 
DDAVP PK. The first two, however, describe DDAVP pharmacokinetics after intravenous dosing, 
which indeed follow biphasic kinetics [37]. Possibly, this biphasic behavior is masked by the 
absorption process after oral dosing. A two compartment model was tried but resulted in a 
significantly worse fit than the one compartment model (ΔOFV = +81.3) The use of a transit model 
could be argued, as the absorption kinetics of DDAVP do seem to be delayed; the mean residence 
time and number of compartments in children have been estimated as 0.237 h and 1.19, 
respectively [15]. The simple first order absorption model was compared with the transit 
compartment model, but this showed no significant improvement (ΔOFVtransit = +8.502). For 
reasons of parsimony, the first order absorption model was hence retained. 
In our study, a population apparent clearance (CL/F) of 4892 L/h was found. This is almost twice 
the value found in the pediatric dataset by Österberg et al. [15]. However, in our study we allowed 
the relative bioavailability to change, depending on the formulation and the fed state. If we 
calculate the population CL/F for a fasted population receiving the lyophilisate formulation, CL/F 
becomes 4892/(1+0.3208+1.011) = 2098 L/h, which corresponds with the reported value of 2330 
L/h by Österberg et al.[15]. The same reasoning can be followed for the apparent volume of 
distribution (Vd/F). However, to compare both values correctly, Vd/F should be calculated for the 
average body weight from the full Österberg dataset (28 kg [15]). Vd/F then becomes 
23346∗(28/45.5)0.4020 = 8237 L, which corresponds to the reported value of 8510 L [15]. 
The bioequivalence between 200 µg tablet and 120 µg lyophilisate found in adults [10], [11], 
[37] could not be supported by the current analysis. The statistical significance of the formulation 
effect is apparent from our model, suggesting that the 120 µg lyophilisate is 32.1% more 
bioavailable than the 200 µg tablet. In adults, this value was found to be (200/120 – 1) = 66.7% for 
a similar strength lyophilisate and tablet. Indeed, when a lyophilisate dose of 150 µg (33.3% lower 
than 200 µg) is simulated (Figure 7), the desmopressin exposure of the two formulations in children 
shows a much better overlap. A possible explanation for this phenomenon could be a reduced 
sublingual absorption in children, caused by either the lower surface area compared to adults, or 
the fact that the lyophilisate is swallowed sooner by children. This could be formally tested in a 
two-period cross-over clinical bioequivalence trial.  
The effect of food intake was also found to be clinically significant. Attributing this effect 
exclusively to food intake might be considered too simplistic, as all fasted patients originated from 
the Österberg study and all fed patients originated from the De Bruyne study, which means other 
factors might confound our analysis.  There are two major differences between the studies: the 
bioanalytical method and the level of hydration. Since the two analytical methods were both 
validated and had a similar linear range, it seems unlikely that this has confounded our estimate 
for food effect to any significant degree. In the De Bruyne study, hydration was maintained by oral 
water administration, 5 hours after dose. Patients in the Österberg study, however, drank 1.5% of 
their body weight as water during 30 minutes after which urinary output loss was replaced with an 
equivalent amount of tap water [14], [15]. Notwithstanding this difference in hydration method, it 
was previously shown that hydration does not significantly influence the PK of DDAVP [35] and it is 
thus highly improbable that the difference between the two study groups can be attributed to this. 
However, between-study-variability might still be present in this effect parameter, as is e.g. 
indicated by the large difference in power curve for a two-period cross-over bioequivalence study 
in respectively the fed (20 patients for 80% power) and fasted population (250 patients).  
As children are not always fasted when they take DDAVP (right before bedtime), this food 
effect can have consequences for the optimal dosing. Even though the effect on the maximal 
response might be negligible, as it is in adults, there might be an influence on the duration of 
action [13]. 
An effect of WT on Vd/F was also found, indicating that dose adjustment could be necessary to 
maximize efficacy in this pediatric population. However, the extent of the body weight influence is 
quite unclear from these data, as the exponent of the power relation exhibits quite a large 
uncertainty. More informative trials can result in smaller CIs for this (and other) parameters. 
Indeed, although model evaluation was positive, the amount of information in the data seems to 
be exhausted in this (relatively simple) model. This is e.g. clear from the failure to additionaly 
estimate an IIV on CL and ka. However, the variability of CL in the population is still somewhat 
captured by the model, as CL and Vd are apparent clearance and volume of distribution, which are 
correlated via the bioavailability F. This way, the IIV on CL is partially captured by the IIV on F and 
Vd.  Ka, and especially its IIV, should be estimated though, which is why a new trial with more 
intensive sampling of the absorption region is needed. 
Therefore, a sensitivity analysis was conducted in order to suggest sampling times for a new 
trial. More intensive sampling in the absorption phase is advisable, as is proposed by both the LSA 
as well as the OED. We suggest to design the trial according to the LSA results, as these time points 
are more practical in a clinical setting, and the OED was only 1.34 times more efficient than the 
LSA-design. This design was based on 8 samples, while theoretically speaking 3 sampling points 
(the number of parameters in the model) should be sufficient [34]. However, as the follow-up 
study will also investigate PD and due to logistical risks, more samples are preferable.  
As the difference between two formulations is not only a matter of PK, PD will also be 
monitored in this new trial. It was e.g. demonstrated in adults that there is a significant effect of 
sex on the DDAVP PD [38]. This effect is thought to be caused by a difference in V2-receptor 
expression [39] and should also be investigated in children. As our study is based exclusively on PK 
data, no inferences about the optimal sampling scheme for PD analysis could be made. In the 
newly designed trial, PD characteristics such as urine volume and plasma osmolality will be 
measured after which a population approach will be used to gain knowledge about the complete 
PK/PD behavior of DDAVP in the pediatric population. 
In conclusion, in this analysis we have presented evidence for an effect of body weight and fed 
state on the pharmacokinetics of desmopressin in children. Furthermore, the relative 
bioavailability between the lyophilisate and tablet formulations is probably not the same in 
children as in adults. We should be reluctant to accept bioequivalence in children based on adult 
data alone. Our study also offers suggestions for optimizing the sampling design of a new trial and 
a sample size calculation for a bioequivalence trial was also provided.  
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